THE AMYGDALA IN ALZHEIMERʼS DISEASE, AGING AND CORONARY ARTERY DISEASE; INCIDENCE OF SENILE PLAQUES AND ALTERED CHEMISTRY

1989 ◽  
Vol 48 (3) ◽  
pp. 334 ◽  
Author(s):  
D. L. Sparks ◽  
J. C. Hunsaker ◽  
J. L. Henson ◽  
W. R. Markesbery
1975 ◽  
Author(s):  
P. Steele ◽  
E. Genton

A role for platelets in the etiology of coronary artery disease (CAD) and its complications has been suggested. In 68 men with angiographically defined CAD platelet survival (SURV) (51Chromium) was shortened (3.2±.04 days; AVE±SEM; normal 3.7±.04 days; p < 0.001) and 41 (60%) had shortened SURV (< 3.3 days). SURV did not correlate with severity of CAD, angina, or history of infarction. Of 37 with hyperlipoproteinemia SURV was shortened (3.1 ±.12 days) in 27 (73%) and different from 31 with normal lipids (3.3±. 12 days; p < 0.05). SURV was performed in 35 following aorto-coronary saphenous vein bypass (ACB). Of 15 with all grafts open, SURV was normal (3.5±.11 days) in 10 (67%). Of 20 with one or more grafts occluded SURV was shortened (2.6±.08 days) in 19 (95%). In 11 with normal SURV, one of 23 (4%) grafts was occluded while in 24 with shortened SURV 26 of 46 (56%) grafts were occluded, Clofibrate prolonged shortened SURV (2.6 ±.09 to 3.4±14 days; p < 0.001) and altered lipids. Sulfinpyrazone prolonged shortened SURV (2.8 ±.12 to 3.6 ±.21 days; p < 0.001) and failed to alter lipids. Data suggest that shortened SURV is frequently present in CAD, can be altered by platelet suppressant agents and is associated with ACB occlusion.


2005 ◽  
Vol 104 (3) ◽  
pp. 269-274 ◽  
Author(s):  
Bonni Syeda ◽  
Suzanne Roedler ◽  
Christoph Schukro ◽  
Nabil Yahya ◽  
Andreas Zuckermann ◽  
...  

1990 ◽  
Vol 11 (6) ◽  
pp. 601-607 ◽  
Author(s):  
D.Larry Sparks ◽  
John C. Hunsaker ◽  
Stephen W. Scheff ◽  
Richard J. Kryscio ◽  
Jana L. Henson ◽  
...  

2015 ◽  
Vol 25 (suppl_3) ◽  
Author(s):  
IR Dégano ◽  
I Subirana ◽  
V Bongard ◽  
M Pereira ◽  
C Meisinger ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document